

Exhibit 14

From: Dan Alminana <dan@elysiumhealth.com>
Sent: Fri, 27 Dec 2013 22:40:45 +0000 (UTC)
To: Eric Marcotulli <eric@elysiumhealth.com>
Cc: Frank Jaksch <Frank.Jaksch@chromadex.com>
Subject: Re: Elysium Health

Frank,
Thanks for passing these documents along. We took a quick read through both and have a couple of comments prior to sending them to our legal team:

Supply Agreement:

- Please provide Exhibit B “Niagen Specifications”. We will need this to conduct a complete review of the document.
- We noticed that the Valid Claim and Net Sales definitions were deleted. We will need these inserted back in to be sure we are paying the royalty on the proper sales base. This also includes the formula, much like that in the Thorne deal, that relates to a “Combined Product”.

License Agreement

- Please provide Exhibit A “Brand Usage Guidelines”. We will need this to conduct a complete review of the document.

Thanks,
Dan

On Dec 27, 2013, at 9:03 AM, Eric Marcotulli <eric@elysiumhealth.com> wrote:

Thanks Frank. We will review and circle back today if there are any questions.

Eric

Sent from my iPhone.

On Dec 27, 2013, at 11:27 AM, "Frank Jaksch" <Frank.Jaksch@chromadex.com> wrote:

Eric,

Attached are the following:

1. Revised “supply agreement”
2. New trademark license agreement with royalty terms. As we discussed this agreement give Elysium the “option” to use the Niagen brand, but it is not a requirement.

Let me know if you have any questions before you send it to your legal folks.

EXHIBIT 14
Page 233

Frank Jaksch

Founder and CEO

<image002.jpg>

10005 Muirlands Blvd., Suite G

Irvine, CA 92618 USA

Tel: +1.949.419.0288

Fax: +1.949.419.0294

frank.jaksch@chromadex.com

www.chromadex.com

CONFIDENTIALITY NOTICE

This email is the property of ChromaDex, Inc and/or its relevant affiliates and contains confidential and privileged material for the sole use of the intended recipient(s). Any review, use, distribution or disclosure by or to others is strictly prohibited. If you are not the intended recipient (or authorized to receive for the recipient), please contact the sender at 949.419.0288 or reply to ChromaDex, Inc at webmaster@chromadex.com and delete all copies of the message.

<Trademark License Agreement 122613 Elysium clean.doc>

<SF-#5453308-v2-Elysium_Health_-_License__Supply_Agreement_with_ChromaDex 122613 HVB revision.doc>